Tango Therapeutics (NASDAQ:TNGX) Now Covered by Mizuho

Mizuho began coverage on shares of Tango Therapeutics (NASDAQ:TNGX) in a research report sent to investors on Monday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $19.00 target price on the stock.

A number of other equities analysts have also issued reports on TNGX. Guggenheim increased their target price on shares of Tango Therapeutics from $12.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Wolfe Research started coverage on shares of Tango Therapeutics in a report on Tuesday, November 18th. They issued a “peer perform” rating for the company. Piper Sandler raised their price objective on shares of Tango Therapeutics from $11.00 to $14.00 and gave the company an “overweight” rating in a research note on Friday, January 16th. Stifel Nicolaus started coverage on Tango Therapeutics in a research report on Wednesday, December 3rd. They issued a “buy” rating and a $15.00 target price for the company. Finally, Wall Street Zen raised Tango Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, December 13th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $15.50.

Tango Therapeutics Stock Performance

Shares of TNGX opened at $12.73 on Monday. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of -13.69 and a beta of 1.75. Tango Therapeutics has a one year low of $1.03 and a one year high of $13.60. The stock’s fifty day moving average is $11.08 and its 200-day moving average is $9.08.

Insider Activity at Tango Therapeutics

In other Tango Therapeutics news, Director Barbara Weber sold 30,519 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total transaction of $374,162.94. Following the completion of the sale, the director directly owned 1,629,254 shares of the company’s stock, valued at approximately $19,974,654.04. This represents a 1.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Adam Crystal sold 18,452 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total transaction of $226,221.52. Following the completion of the transaction, the insider owned 187,218 shares of the company’s stock, valued at approximately $2,295,292.68. The trade was a 8.97% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 59,288 shares of company stock worth $726,871 in the last quarter. 7.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Tango Therapeutics

A number of large investors have recently made changes to their positions in TNGX. Invesco Ltd. boosted its stake in Tango Therapeutics by 138.8% in the 1st quarter. Invesco Ltd. now owns 70,517 shares of the company’s stock worth $97,000 after purchasing an additional 40,983 shares during the period. AQR Capital Management LLC purchased a new stake in shares of Tango Therapeutics in the first quarter valued at $195,000. Dynamic Technology Lab Private Ltd boosted its position in shares of Tango Therapeutics by 139.7% in the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock worth $35,000 after buying an additional 15,037 shares during the period. Woodline Partners LP boosted its position in shares of Tango Therapeutics by 28.3% in the first quarter. Woodline Partners LP now owns 506,188 shares of the company’s stock worth $693,000 after buying an additional 111,791 shares during the period. Finally, Jane Street Group LLC grew its holdings in shares of Tango Therapeutics by 270.6% during the first quarter. Jane Street Group LLC now owns 352,897 shares of the company’s stock valued at $483,000 after buying an additional 257,668 shares in the last quarter. Institutional investors and hedge funds own 78.99% of the company’s stock.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.